Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse

Human Molecular Genetics

Volumn 12, Issue 18, 2003, Pages 2277-2291

  Itier, Jean Michel ^a   Ibáñez, Pablo ^b   Mena, Maria Angeles ^c   Abbas, Nacer ^b   Cohen Salmon, Charles ^b   Bohme, Georg Andrees ^a   Laville, Michel ^a   Pratt, Jeremy ^a   Corti, Olga ^b   Pradier, Laurent ^a   Ret, Gwénnäelle ^a   Joubert, Chantal ^b   Periquet, Magali ^b   Araujo, Francisco ^a   Negroni, Julia ^b   Casarejos, María José ^c   Canals, Santiago ^c   Solano, Rosa ^c   Serrano, Alba ^d   Gallego, Eva ^d   Sánchez, Marina ^d   Denèfle, Patrice ^a   Benavides, Jesús ^a   Tremp, Günter ^a   Rooney, Thomas A ^a   Brice, Alexis ^b   García de Yébenes, Justo ^d   more..

^a SANOFI   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; GLUTATHIONE; PARKIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL DEATH; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; GENE INACTIVATION; GENE MUTATION; LIMBIC CORTEX; MESENCEPHALON; MOTOR DYSFUNCTION; MOUSE; MOUSE MUTANT; NERVE ENDING; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ALLELES; ALPHA-METHYLTYROSINE; ANIMALS; BASE SEQUENCE; BEHAVIOR, ANIMAL; BODY TEMPERATURE; BODY WEIGHT; CATECHOLAMINES; CELLS, CULTURED; DOPAMINE; ENZYME INHIBITORS; EXONS; FEMALE; GENE SILENCING; HOMOZYGOTE; INTRONS; MALE; MICE; MICE, TRANSGENIC; MONOAMINE OXIDASE; NEURONS; NEUROTRANSMITTER UPTAKE INHIBITORS; SEQUENCE DELETION; UBIQUITIN-PROTEIN LIGASES;

ANIMALIA;

EID: 10744221310     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/ddg239     Document Type: Review

References (91)

1. de Rijk, M.C., Launer, L.J., Berger, K., Breteler, M.M., Dartigues, J.F., Baldereschi, M., Fratiglioni, L., Lobo, A., Martinez-Lage, J., Trenkwalder, C. and Hofman, A. (2000) Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group, Neurology, 54, S21-23.
2. Elbaz, A., Bower, J.H., Maraganore, D.M., McDonnell, S.K., Peterson, B.J., Ahlskog, J.E., Schaid, D.J. and Rocca, W.A. (2002) Risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol., 55, 25-31.
3. Jankovic, J. (1992) Pathophysiology and clinical assessment of motor symptoms in Parkinson's disease. In Koller, W.C. (ed.), Handbook of Parkinson's Disease. Marcel Dekker, New York, pp. 129-157.
4. Louis, E.D., Levy, G., Cote, L.J., Mejia, H., Fahn, S. and Marder, K. (2002) Diagnosing Parkinson's disease using videotaped neurological examinations: validity and factors that contribute to incorrect diagnoses. Mov. Disord., 17, 513-517.
5. Forno, L.S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol., 55, 259-272.
6. Dickson, D.W. (2001) Alpha-synuclein and the Lewy body disorders. Curr. Opin. Neurol., 14, 423-432.
7. Schneider, J.A., Bienias, J.L., Gilley, D.W., Kvarnberg, D.E., Mufson, E.J. and Bennett, D.A. (2002) Improved detection of substantia nigra pathology in Alzheimer's disease. J. Histochem. Cytochem., 50, 99-106.
8. Beal, M.F. (2002) Oxidatively modified proteins in aging and disease. Free Radic. Biol. Med., 32, 797-803.
9. Schapira, A.H., Gu, M., Taanman, J.W., Tabrizi, S.J., Seaton, T., Cleeter, M. and Cooper, J.M. (1998) Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol., 44, S89-98.
10. Betarbet, R., Sherer, T.B. and Greenamyre, J.T. (2002) Animal models of Parkinson's disease. Bioessays, 24, 308-318.
11. Feger, J., Pessiglione, M., Francois, C., Tremblay, L. and Hirsch, E. (2002) Experimental models of Parkinson's disease. Ann. Pharm. Fr., 60, 3-21.
12. Gerlach, M. and Riederer, P. (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm., 103, 987-1041.
13. Grunblatt, E., Mandel, S. and Youdim, M.B. (2000) Neuroprotective strategies in Parkinson's disease using the models of 6- hydroxydopamine and MPTP. Ann. NY Acad. Sci., 899, 262-273.
14. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
15. Le, W.D., Xu, P., Jankovic, J., Jiang, H., Appel, S.H., Smith, R.G. and Vassilatis, D.K. (2003) Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet., 33, 85-89.
16. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
17. Lucking, C.B., Durr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B.S., Meco, G., Denefle, P., Wood, N.W. et al. (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. New Engl. J. Med., 342, 1560-1567.
18. Periquet, M., Latouche, M., Lohmann, E., Rawal, N., De Michele, G., Ricard, S., Teive, H., Fraix, V., Vidailhet, M., Nicholl, D. et al. (2003) Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain, 126, 1271-1278.
19. Abbas, N., Lucking, C.B., Ricard, S., Durr, A., Bonifati, V., De Michele, G., Bouley, S., Vaughan, J.R., Gasser, T., Marconi, R. et al. (1999) A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum. Mol. Genet., 8, 567-574.
20. Hoenicka J., Vidal, L., Morales, B., Ampuero, I., Jimenez-Jimenez, F.J., Berciano, J., del Ser, T., Jimenez, A., Ruiz, P.G. and de Yebenes, J.G. (2002) Molecular findings in familial Parkinson disease in Spain. Arch. Neurol., 59, 966-970.
21. Hayashi, S., Wakabayashi, K., Ishikawa, A., Nagai, H., Saito, M., Maruyama, M., Takahashi, T., Ozawa, T., Tsuji, S. and Takahashi, H. (2000) An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov. Disord., 15, 884-888.
22. Mori, H., Kondo, T., Yokochi, M., Matsumine, H., Nakagawa-Hattori, Y., Miyake, T., Suda, K. and Mizuno, Y. (1998) Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology, 51, 890-892.
23. Takahashi, H., Ohama, E., Suzuki, S., Horikawa, Y., Ishikawa, A., Morita, T., Tsuji, S. and Ikuta, F. (1994) Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology, 44, 437-441.
24. Van de Warrenburg, B.P., Lammens, M., Lucking, C.B. Denefle, P., Wesseling, P., Booij, J., Praamstra, P., Quinn, N., Brice, A. and Horstink, M.W. (2001) Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology, 56, 555-557.
25. Farrer, M., Chan, P., Chen, R., Tan, L., Lincoln, S., Hernandez, D., Forno, L., Gwinn-Hardy, K., Petrucelli, L. et al. (2001) Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol., 50, 293-300.
26. Klein, C., Pramstaller, P.P., Kis, B., Page, C.C., Kann, M., Leung, J., Woodward, H., Castellan, C.C., Scherer, M., Vieregge, P. et al. (2000) Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann. Neurol., 48, 65-71.
27. Morales, B., Martínez, A., Gonzalo I. Vidal, L., Gomez-Tortosa, E., Rabano, A., Ampuero, I., Sánchez, M., Hoenicka, J. and Garcia de Yebenes, J. (2002) Steele-Richardson-Olzewsky syndrome in a patient with a single C212Y mutation in the parkin protein. Mov. Disord., 17, 1374-1380.
28. Lohmann, E., Periquet, M., Bonifati, V., Wood, N.W., De Michele, G., Bonnet, A.M., Fraix, V., Broussolle, E., Horstink, M.W., Vidailhet, M., Verpillat, P. et al. (2003) How much phenotypic variation can be attributed to parkin genotype? The French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Ann. Neurol., 54, 176-185.
29. West, A., Periquet, M., Lincoln, S., Lucking, C.B., Nicholl, D., Bonifati, V., Rawal, N., Gasser, T., Lohmann, E., Deleuze J.F. et al. (2002) Complex relationship between Parkin mutations and Parkinson disease. Am. J. Med. Genet., 114, 584-591.
30. Zhang, Y., Gao, J., Chung, K.K., Huang, H., Dawson, V.L. and Dawson, T.M. (2000) Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA, 97, 13354-13359.
31. Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y. and Takahashi, R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell, 105, 891-902.
32. Chung, K.K., Zhang, Y., Lim, K.L., Tanaka, Y., Huang, H., Gao, J., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med., 7, 1144-1150.
33. Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K.S. and Selkoe, D.J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science, 293, 263-269.
34. Greene, J.C., Whitworth, A.J., Koo, I., Andrews, L.A., Feany, M.B. and Pollanck, L.J. (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA, 100, 4078-4083.
35. Zucker, R.S. (1989). Short-term synaptic plasticity. A. Rev. Neurosci., 12, 13-31.
36. Creager, R., Dunwiddie, T. and Lynch, G. (1980) Paired-pulse and frequency facilitation in the CA1 region of the in vitro rat hippocampus. J. Physiol., 299, 409-424.
37. Dunwiddie, T.V. and Haas, H.L. (1985) Adenosine increases synaptic facilitation in the in vitro rat hippocampus: evidence for a presynaptic site of action. J. Physiol., 369, 365-377.
38. Beites, C.L., Xie, H., Bowser, R. and Trimble, W.S. (1999) The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Nat. Neurosci., 2, 434-439.
39. Diaz-Torga, G., Feierstein, C., Libertun, C., Gelman, D., Kelly, M.A., Low, M.J., Rubinstein, M. and Becu-Villalobos, D. (2002) Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. Endocrinology, 143, 1270-1279.
40. Lipton, J.M. and Clark, W.G. (1986) Neurotransmitters in temperature control. A. Rev. Physiol., 48, 613-623.
41. Boulay, D., Depoortere, R., Perrault, G., Borrelli, E. and Sanger, D.J. (1999) Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists. Neuropharmacology, 38, 1389-1396.
42. Bharath, S., Hsu, M., Kaur, D., Rajagopalan, S. and Andersen, J.K. (2002) Glutathione, iron and Parkinson's disease. Biochem. Pharmac., 64, 1037-1048.
43. Adams, J.D., Chang, M.L. and Klaidman, L.K. (2001) Parkinsons Disease-redox mechanisms. Curr. Med. Chem., 8, 809-814.
44. Riederer, P., Sofic, E., Rausch, W.D., Schmidt, B., Reynolds, G.P., Jellinger, K. and Youdim, M.B. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem., 52, 515-520.
45. Sofic, E., Lange, K.W., Jellinger, K. and Riederer, P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett., 142, 128-130.
46. Hyun, D-H., Lee, M.H., Hattori, N., Kubo, S. I., Mizuno, Y., Halliwell, B. and Jenner, P. (2002) Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J. Biol. Chem., 277, 28572-28577.
47. Mena, M.A., Davila, V., Bogaluvsky, J. and Sulzer, D. (1998) A synergistic neurotrophic response to 1-dihydroxyphenylalanine and nerve growth factor. Mol. Pharmac., 54, 678-686.
48. Rodriguez-Marín, E., Canals, S., Casarejos, M.J., de Bernardo, S., Handler, A. and Mena, M.A. (2001) L-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells. J. Neurochem., 78, 535-545.
49. Canals, S., Casarejos, M.J., de Bernardo, S., Rodriguez-Marín, E. and Mena, M.A. (2001) Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease. J. Neurochem., 79, 1183-1195.
50. Di Chiara, G. and Imperato, A. (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA, 85, 5274-5278.
51. Rudnick, G. and Wall, S.C. (1992) The molecular mechanism of 'ecstasy' [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl Acad. Sci. USA, 89, 1817-1821.
52. Sulzer, D., Maidment, N.T. and Rayport, S. (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem., 60, 527-535.
53. Sulzer, D., Chen, T.K., Lau, Y.Y., Kristensen, H., Rayport, S. and Ewing, A. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci., 15, 4102-4108.
54. Giros, B., Jaber, M., Jones, S.R., Wightman, R.M. and Caron, M.G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 379, 606-612.
55. Patel, J., Mooslehner, K.A., Chan, P.M. Emson, P.C. and Stamford, J.A. (2003) Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. J. Neurochem., 85, 898-910.
56. Shuldinger, S. (1994) A molecular glimpse of vesicular monoamine transporters. J. Neurochem., 62, 2067-2078.
57. Miller, G.W., Erickson, J.D., Perez, J.T., Penland, S.N., Mash, D.C., Rye, D.B. and Levey, A.I. (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol., 156, 138-148.
58. Fernandez, H.H., Friedman, J.H., Fischman, A.J., Noto, R.B. and Lannon, M.C. (2001) Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease? Med. Sci. Monit., 7, 1339-1343.
59. Moll, G.H., Mehnert, C., Wicker, M., Bock, N., Rothenberger, A., Ruther, E. and Huether, G. (2000) Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain Res. Dev. Brain Res., 7, 251-257.
60. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 3, 1653-1661.
61. Cabin, D.E., Shimazu, K., Murphy, D., Cole, N.B., Gottschalk, W., McIlwain, K.L., Orrison, B., Chen, A., Ellis, C.E., Paylor, R. et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci., 22, 8797-8807.
62. Kubo, S.I., Kitami, T., Noda, S., Shimura, H., Uchiyama, Y., Asakawa, S., Minoshima, S., Shimizu, N., Mizuno, Y. and Hattori, N. (2001) Parkin is associated with cellular vesicles. J. Neurochem., 78, 42-54.
63. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A. et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239-252.
64. Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski, J.Q. and Lee, V.M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron, 34, 521-533.
65. Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H.K. and Brundin, P. (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem., 277, 38884-38894.
66. Stefanis, L., Larsen, K.E., Rideout, H.J., Sulzer, D. and Greene, L.A. (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci., 21, 9549-9560.
67. Owen, A.M., Iddon, J.L., Hodges, J.R., Summers, B.A. and Robbins, T.W. (1997) Spatial and non-spatial working memory at different stages of Parkinson's disease. Neuropsychologia, 35, 519-532.
68. Heberlein, I., Ludin, H.P., Scholz, J. and Vieregge, P. (1998) Personality, depression, and premorbid lifestyle in twin pairs discordant for Parkinson's disease. J. Neurol. Neurosurg. Psychiat., 64, 262-266.
69. Menza, M. (2000) The personality associated with Parkinson's disease. Curr. Psychiatry Rep., 2, 421-426.
70. O'Connor, L., Berry, J., Weiss, J. and Gilbert, P. (2002) Guilt, fear, submission, and empathy in depression. J. Affect. Disord., 71, 13-19.
71. Cummings, J.L. (1992) Depression and Parkinson's disease. Am. J. Psychiat., 149, 443-454.
72. Michel, P.P. and Hefti, F. (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res., 26, 428-435.
73. Mena, M.A., Pardo, B., Casarejos, M.J., Fahn, S. and Garcia de Yebenes, J. (1992) Neurotoxicity of levodopa on catecholamine-rich neurons. Mov. Disord., 7, 23-31.
74. Murer, M.G., Dziewczapolski, G., Menalled, L.B., Garcia, M.C., Agid, Y., Gershanik, O. and Raisman-Vozari, R. (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol., 43, 561-575.
75. Troadec, J.D., Marien, M., Darios, F., Hartmann, A., Ruberg, M., Colpaert, F. and Michel, P.P. (2001) Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J. Neurochem., 79, 200-210.
76. 1/2) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Mol. Pharmac., 62, 1043-1052.
77. Mena, M.A., Casarejos, M.J., Carazo, A., Paino, C.L. and Garcia de Yebenes, J. (1996) Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity. Neuroreport, 7, 441-445.
78. Mena, M.A., Casarejos, M.J. and Garcia de Yebenes, J. (1999) The effect of glia-conditioned medium on dopamine neurons in culture. Modulation of apoptosis, tyrosine hydroxylase expression and 1-methyl-4-phenylpyridinium toxicity. J. Neural Transm., 106, 1105-1123.
79. Pardo, B., Mena, M.A., Casarejos, M.J., Paino, C.L. and De Yebenes, J.G. (1995). Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res., 682, 133-143.
80. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
81. Stichel, C., Augustin, M., Kühn, K., Zhu, X., Engels, P., Ullmer, C. and Lübbert, H. (2000) Parkin expression in adult mouse brain. Eur. J. Neurosci., 12, 1-15.
82. Jaffard, R., Dubois, M. and Galey, D. (1981) Memory of a choice direction in a T maze as measured by spontaneous alternation in mice: effects of intertribal interval and reward. Behav. Proc., 6, 11-21.
83. Hirsch, M.D. and Helke, C.J. (1988) Bulbospinal thyrotropin-releasing hormone projections to the intermediolateral cell column: a double fluorescence immunohistochemical-retrograde tracing study in the rat. Neuroscience, 25, 625-637.
84. Hunot, S., Brugg, B., Ricard, D., Michel, P.P., Muriel, M.P., Ruberg, M., Faucheux, B.A., Agid, Y. and Hirsch, E.C. (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl Acad. Sci. USA, 94, 7531-7536.
85. Mena, M.A., Casarejos, M.J., Bonin, A., Ramos, J.A. and Garcia de Yebenes, J. (1995) Effects of dibutyryl cyclic AMP and retinoic acid on the differentiation of dopamine neurons: prevention of cell death by dibutyryl cyclic AMP. J. Neurochem., 65, 2612-2620.
86. Handler, A., Lobo, M.V.T., Alonso, F.J., Paino, C.L. and Mena, M.A. (2000) Functional implications of the noradrenergic-cholinergic switch induced by retinoic acid in NB69 neuroblastoma cells. J. Neurosci. Res., 60, 311-320.
87. Carlsson, A. and Lindqvist, M. (1973) Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J. Pharm. Pharmac., 25, 437-440.
88. Garcia de Yebenes, J., Carlsson, A. and Mena, M.A. (1978) The effect of taurine on motor behavior, body temperature and monoamine metabolism in rat brain. Naunyn-Smiedeberg Archv. Pharmac., 304, 95-99.
89. Tietze, F. (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem., 27, 502-522.
90. Griffith, O.W. (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem., 106, 202-212.
91. Mena, M.A., Casarejos, M.J., Carazo, A., Paino, C.L. and Garcia de Yebenes, J. (1997) Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J. Neural. Transm., 104, 317-328.